Arnold C. Hanish net worth and biography

Arnold Hanish Biography and Net Worth

Director of Omeros

Arnold C. Hanish has served on our board of directors since September 2012. From 1994 until his retirement in December 2012, Mr Hanish served as vice president and chief accounting officer at Eli Lilly and Company. Prior to his appointment as chief accounting officer, Mr Hanish held a number of senior financial positions at Eli Lilly. Before Eli Lilly, he held various positions at Arthur Young & Company (currently Ernst & Young) for nearly 14 years. Mr Hanish currently serves as a member of the board of directors of Salarius Pharmaceuticals and was a member of the Deloitte and Touche Audit Quality Review Council from 2013 through December 2023. Mr Hanish was a member of the Standing Advisory Group of the Public Company Accounting Oversight Board from 2004 through 2008 and from 2011 through 2012. In addition, he served from 2007 to 2010 as the chairperson of Financial Executives International’s Committee on Corporate Reporting. Mr Hanish was inducted into the Financial Executives International Hall of Fame in 2016. He is a Certified Public Accountant and earned his BA in accounting from the University of Cincinnati.

What is Arnold C. Hanish's net worth?: The estimated net worth of Arnold C. Hanish is at least $97.10 thousand as of August 27th, 2026. Mr. Hanish owns 5,000 shares of Omeros stock worth more than $97,100 as of September 9th. This net worth evaluation does not reflect any other assets that Mr. Hanish may own. Learn More about Arnold C. Hanish's net worth.
How do I contact Arnold C. Hanish?: The corporate mailing address for Mr. Hanish and other Omeros executives is 201 ELLIOT AVENUE WEST, SEATTLE WA, 98119. Omeros can also be reached via phone at (206) 676-5000 and via email at [email protected]. Learn More on Arnold C. Hanish's contact information.
Has Arnold C. Hanish been buying or selling shares of Omeros?: Over the course of the past ninety days, Arnold C. Hanish has sold $282,150.00 of Omeros stock. Most recently, Arnold C. Hanish sold 10,000 shares of the business's stock in a transaction on Thursday, August 27th. The shares were sold at an average price of $18.95, for a transaction totalling $189,500.00. Following the completion of the sale, the director now directly owns 5,000 shares of the company's stock, valued at $94,750. Learn More on Arnold C. Hanish's trading history.
Who are Omeros' active insiders?: Omeros' insider roster includes David Borges (CAO), Thomas Cable (Director), Gregory Demopulos (CEO), Peter Demopulos (Director), Arnold Hanish (Director), and Michael Jacobsen (CAO). Learn More on Omeros' active insiders.
Are insiders buying or selling shares of Omeros?: During the last year, insiders at the biopharmaceutical company sold shares 10 times. They sold a total of 133,406 shares worth more than $2,236,579.60. The most recent insider tranaction occured on August, 31st when VP Peter B Cancelmo sold 25,000 shares worth more than $463,500.00. Insiders at Omeros own 10.5% of the company. Learn More about insider trades at Omeros.
Information on this page was last updated on 8/31/2026.

Arnold C. Hanish Insider Trading History at Omeros

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/27/2026	Sell	10,000	$18.95	$189,500.00	5,000
8/26/2026	Sell	5,000	$18.53	$92,650.00	5,000
5/22/2023	Sell	5,000	$6.46	$32,300.00	35,067
1/3/2013	Buy	2,000	$5.58	$11,160.00

Arnold C. Hanish Buying and Selling Activity at Omeros

Omeros Company Overview

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

Today's Range

Now: $19.39

$18.93

$19.55

50 Day Range

MA: $13.89

$9.22

$19.32

2 Week Range

Now: $19.39

$3.94

$19.65

Volume

1,484,966 shs

Average Volume

1,693,492 shs

Market Capitalization

$1.40 billion

P/E Ratio

15.15

Dividend Yield

N/A

Beta

2.6